Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts

Cancer Research

Volumn 58, Issue 4, 1998, Pages 685-690

  Ishikawa, Tohru ^a   Sekiguchi, Fumiko ^a   Fukase, Yu ^a   Sawada, Noriaki ^a   Ishitsuka, Hideo ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; TEGAFUR; THYMIDINE PHOSPHORYLASE; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLOXURIDINE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; OXIDOREDUCTASES; THYMIDINE PHOSPHORYLASE;

EID: 0032520168     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Giovanella, B. C., Stehlin, J. S., Shepard, R. C, and Williams, L. J. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer (Phila.), 52: 1146-1152, 1983.
2. Fujita, M., Hayata, S., and Taguchi, T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patients. J. Surg. Oncol., 15: 211-219, 1980.
3. Hamburger, A. W., and Salmon, S. E. Primary bioassay of human tumor stem cells. Science (Washington DC), 197: 461-463, 1977.
4. Bogden, A. E., Haskell, P. M., and LePage, D. J. Growth of human tumor xenografts implanted under the renal capsule of normal immunocompetent mice. Exp. Cell Biol., 47: 281-293, 1979.
5. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
6. el-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol., 9: 79-87, 1997.
7. Yamauchi, H., O'Neil, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S., and Hayes, D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 2518-2525, 1997.
8. Horwitz, K. B., McGuire, W. L., Pearsons, O. H., and Segaloff, A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (Washington DC), 189: 726-727, 1975.
9. Caldarola, L., Volterrani, P., Caldarola, B., Lai, M., Jayme, A., and Gaglia, P. The influence of hormone receptors and hormonal adjuvant therapy on disease-free survival in breast cancer: a multifactorial analysis. Eur. J. Cancer & Clin. Oncol. 22: 151-155, 1986.
10. Ishitsuka, H., Miwa, M., Ishikawa, T., Ura, M., Sawada, N., Nishida, M., Fukase, Y., Yamamoto, T., Mori, K., Arasaki, M., Umeda, I., and Shimma, N. Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc. Am. Assoc. Cancer Res., 36: 407, 1995.
11. Kono, H., Hara, Y., Sugata, S., Karube, Y., Matsushima, Y., and Ishitsuka, H. Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (Tokyo), 31: 175-178, 1983.
12. Heggie, G. D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
13. Naguib, F. N. M., el Kouni, M. H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45: 5405-5412, 1985.
14. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Polin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
15. Ishikawa, T., Utoh, M., Sawada, N., Nishida, M., Fukase, Y., Sekiguchi, F., and Ishitsuka, H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem. Pharmacol., in press, 1998.
16. Miyadera, K., Sumizawa, T., Haraguchi, M., Yoshida, H., Konstanty, W., Yamada, Y., and Akiyama, S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res., 55: 1687-1690, 1995.
17. Fox, S. B., Westwood, M., Moghaddam, A., Comley, M., Turley, H., Whitehouse, R. M., Bicknell, R., Gatter, K. C., and Harris, A. L. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br. J. Cancer, 73: 275-280, 1996.
18. Toide, H., Akiyoshi, H., Minato, Y., Okuda, H., and Fujii, S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann, 68: 553-560, 1977.
19. Takechi, T., Uchida, J., Fujioka A., and Fukushima M. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int. J. Oncol., 11: 1041-1044, 1997.
20. Toi, M., Ohashi, T., Takatsuka, Y., Shin, E., Inaji, H., Yamamoto, Y., and Tominaga, T. Selective effect of adjuvant 5′-deoxy-5-fluorouridine (5′-DFUR) treatment for thymidine phosphorylase positive tumors in primary breast cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 481, 1997.
21. Yamamoto, Y., Toi, M., and Tominaga, T. Prediction of the effect of 5′-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol. Rep., 3: 863-865, 1996.
22. Lenz, H. J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1995.
23. Eda, H., Fujimoto, K., Watanabe, S., Ura, M., Hino, A., Tanaka, Y., Wada, K., and Ishitsuka, H. Cytokine induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32: 333-338, 1993.
24. Tanaka, Y., Endo, M., Ouchi, K., Mori, K., and Ishitsuka, H. Augmentation of antitumor activity of 5′-DFUR by IL-12 in murine tumor models (in Japanese). J. Jpn. Soc. Cancer Ther., 31: 736, 1996.
25. Ishitsuka, H., Ishikawa, T., Fukase, Y., Sawada, N., Tanaka, Y., Ouchi, K., Yoshikubo, T., and Nishida, M. Capecitabine and the dThdPase up-regulators IFNγ or taxol showed synergistic activity in human cancer xenografts. Proc. Am. Assoc. Cancer Res., 37: 405, 1996.
26. Baccanari, D. P., Davis, S. T., Knick, V. C., and Spector, T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc. Natl. Acad. Sci. USA, 90: 11064-11068, 1993.
27. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N., and Fukushima, M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606, 1996.